Current Concepts and Future Prospects for Alzheimer Disease Vaccines

Alzheimer Disease and Associated Disorders

Volumn 18, Issue 1, 2004, Pages 38-43

  Heppner, Frank L ^a   Gandy, Sam ^b   McLaurin, JoAnne ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer disease; Immunization; Vaccines

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; DRUG MECHANISM; HUMAN; IMMUNIZATION; MEMORY; MENINGOENCEPHALITIS; PREVALENCE; PRIORITY JOURNAL; SENILE PLAQUE; TREATMENT WITHDRAWAL; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; ANIMALS; ANTIBODY FORMATION; CLINICAL TRIALS; HUMANS; IMMUNIZATION; MICE; MICE, TRANSGENIC; SENILE PLAQUES; VACCINES;

EID: 1542344385     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200401000-00008     Document Type: Article

References (52)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741-766.
2. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984; 120:885-890.
3. Westermark P, Araki S, Benson MD, et al. Nomenclature of amyloid fibril proteins. Amyloid. 1999;6:63-66.
4. Chishti MA, Yang DS, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562-21570.
5. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979-982.
6. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523-527.
7. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102.
8. Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287-13292.
9. Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050-4058.
10. Kelly PH, Bondolfi L, Hunziker D, et al. Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging. 2003;24:365-378.
11. Lalonde R, Dumont M, Staufenbiel M, et al. Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res. 2002;956:36-44.
12. Van Dam D, D'Hooge R, Staufenbiel M, et al. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci. 2003; 17:388-396.
13. Calhoun ME, Wiederhold KH, Abramowski D, et al. Neuron loss in APP transgenic mice [letter]. Nature. 1998;395:755-756.
14. Hock BJ Jr, Lamb BT. Transgenic mouse models of Alzheimer's disease. Trends Genet. 2001;17(suppl): 7-12.
15. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature. 1999;400:173-177.
16. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916-919.
17. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA. 2003; 100:2023-2028.
18. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982-985.
19. Arendash GW, Gordon MN, Diamond DM, et al. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol. 2001;20:737-744.
20. Lemere CA, Maron R, Spooner ET, et al. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann NY Acad Sci. 2000;920:328-331.
21. Weiner HL, Lemere CA, Maron R, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol. 2000;48:567-579.
22. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452-457.
23. Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002;22: 6331-6335.
24. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46-54.
25. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824-828.
26. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002;8:1263-1269.
27. Gandy S, DeMattos RB, Lemere C, et al. Non-human primates vaccinated with Alzheimer's Aβ develop anti-peptide antibodies and elevated plasma Aβ but sera lack obvious tissue amyloid plaque immunoreactivity. Alzheimer Dis Assoc Disord. (in press).
28. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547-554.
29. Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001;7:369-372.
30. Bacskai BJ, Kajdasz ST, McLellan ME, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002;22:7873-7878.
31. -/- knock-out mice. J Neurosci. 2003;23:8532-8538.
32. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850-8855.
33. DeMattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264-2267.
34. Lemere CA, Spooner ET, LaFrancois J, et al. Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol Dis. 2003;14:10-18.
35. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999,46:860-866.
36. Frenkel D, Solomon B, Benhar I. Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody. J Neuroimmunol. 2000;106:23-31.
37. Solomon B, Koppel R, Hanan E, et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA. 1996;93:452-455.
38. Solomon B, Koppel R, Frankel D, et al. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA. 1997;94: 4109-4112.
39. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379.
40. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448-452.
41. Wilcock DM, DiCarlo G, Henderson D, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23:3745-3751.
42. McGeer PL, McGeer EG. Mechanisms of cell death in Alzheimer disease: immunopathology. J Neural Transm Suppl. 1998;54:159-166.
43. Rogers J, Webster S, Lue LF, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging. 1996;17:681-686.
44. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
45. Monsonego A, Zota V, Karni A, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest. 2003;112:415-422.
46. Monsonego A, Imitola J, Zota V, et al. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells. J Immunol. 2003;171:2216-2224.
47. Aguzzi A, Glatzel M, Montrasio F, et al. Interventional strategies against prion diseases. Nat Rev Neurosci. 2001;2:745-749.
48. Heppner FL, Arrighi I, Kalinke U, et al. Immunity against prions? Trends Mol Med. 2001;7:477-479.
49. Heppner FL, Musahl C, Arrighi I, et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science. 2001; 294:178-182.
50. Sigurdsson EM, Brown DR, Daniels M, et al. Immunization delays the onset of prion disease in mice. Am J Pathol. 2002;161:13-17.
51. Sigurdsson EM, Sy MS, Li R, et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett. 2003;336:185-187.
52. White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 2003;422: 80-83.